Presentation is loading. Please wait.

Presentation is loading. Please wait.

Jennifer L. Hundley, MD, Christie L

Published byArnold Lund Modified over 5 years ago

Similar presentations

Presentation on theme: "Jennifer L. Hundley, MD, Christie L"— Presentation transcript:

1 Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life 
Jennifer L. Hundley, MD, Christie L. Carroll, MD, Wei Lang, PhD, Beverly Snively, PhD, Gil Yosipovitch, MD, Steven R. Feldman, MD, PhD, Joseph L. Jorizzo, MD  Journal of the American Academy of Dermatology  Volume 54, Issue 2, Pages (February 2006) DOI: /j.jaad Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Physician's Global Assessment (PGA) compared with quality of life (QOL) measures. There is greater QOL impairment for patients with more severe disease. QOL impact of dermatomyositis was assessed for patients at different levels of disease severity. There was clinically significant degree of QOL impairment at all levels of disease severity. Greater disease severity was associated with worse QOL. DLQI, Dermatology Life Quality Index. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Comparision of Skindex-16 subscales among dermatomyositis, dermatitis, and psoriasis. Skindex-16 scores for patients with dermatomyositis were compared with published data on dermatitis and psoriasis.11 All scores were normalized to a 0-to-100 scale for comparison. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Jennifer L. Hundley, MD, Christie L"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
Cutaneous myiasis associated with scalp psoriasis

Cutaneous myiasis associated with scalp psoriasis
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs  Joseph F. Fowler, MD, Arindam Ghosh,

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs  Joseph F. Fowler, MD, Arindam Ghosh,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M
Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.
Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

Similar presentations

Ads by Google